Trial Outcomes & Findings for Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide (NCT NCT03298802)

A total of 453 individuals were initially recorded based on early recruitment and screening logs. After applying eligibility criteria and accounting for withdrawals prior to study start, 400 participants were enrolled and began the study.

Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide

Any participants who had a visit to the hospital during the 1-6 weeks postpartum.

Number of participants requiring additional antihypertensive agents in 1-6 weeks postpartum window

Days that participants required to be in-house in the postpartum period

Number of participants that receive one additional doses in the 1-6 weeks postpartum

Number of participants that have a blood pressure greater than 150/90 in the 1-6 weeks postpartum window

Number of participants with any of the following: ICU admission, HELLP syndrome, eclampsia, stroke, renal failure, pulmonary edema, cardiomyopathy or maternal death.

Allergic reactions (anaphylaxis, angioedema, skin rashes including Stevens Johnson and Toxic Epidermal necrolysis)

Number of participants that had additional Hospital Stay, Postpartum Clinic or Emergency room visit, Need for Imaging or other Invasive Procedures within 4-6 weeks of delivery, 4-6 weeks postpartum.